Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis

Area of Science:

• Rheumatology
• Pediatric Autoimmune Diseases
• Pharmacology

Background:

• Juvenile dermatomyositis (JDM) is a rare autoimmune disease affecting children, characterized by muscle weakness and skin rash.
• Refractory and/or severe cases (rsJDM) often require intensive treatment, with corticosteroids and traditional immunosuppressants sometimes insufficient or associated with significant side effects.
• Baricitinib, a Janus kinase (JAK) inhibitor, has shown promise in adult autoimmune conditions, but its efficacy and safety in pediatric rsJDM are less understood.

Purpose of the Study:

• To evaluate the short-term effectiveness and safety of baricitinib in pediatric patients with refractory and/or severe juvenile dermatomyositis (rsJDM).
• To assess the impact of baricitinib on disease activity, including skin rash and muscle function, in a real-world clinical setting.
• To determine baricitinib's role in reducing corticosteroid dosage in children with rsJDM.

Main Methods:

• A single-center retrospective study included 20 children diagnosed with rsJDM.
• Patients received baricitinib in combination with corticosteroids and other immunosuppressive agents.
• Disease severity and treatment outcomes were assessed using the Childhood Myositis Assessment Scale (CMAS), PRINTO remission criteria, and skin disease activity score (skin-DAS) at baseline and at 4, 12, and 24 weeks.

Main Results:

• Significant improvements were observed in skin rash (95% improvement by week 24) and muscle function, with notable increases in CMAS and MMT-8 scores by week 12 and 24.
• At 24 weeks, 75% of patients achieved complete response (CR) and 15% achieved partial response (PR).
• Baricitinib treatment led to a significant reduction in corticosteroid dosage, decreasing by 37% at week 12 and 49% by week 24, with no serious adverse events reported.

Conclusions:

• Baricitinib, when added to traditional immunosuppressants, demonstrates significant efficacy in treating pediatric rsJDM.
• This add-on therapy aids in tapering corticosteroid doses, potentially mitigating long-term side effects associated with prolonged steroid use.
• The study supports baricitinib as a safe and effective treatment option for children with refractory and/or severe juvenile dermatomyositis.